Edmond DE Rothschild Holding S.A. Lowers Holdings in Solventum Co. (NYSE:SOLV)

Edmond DE Rothschild Holding S.A. cut its position in shares of Solventum Co. (NYSE:SOLV) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,331 shares of the company’s stock after selling 553 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Solventum were worth $1,805,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Modus Advisors LLC purchased a new position in Solventum during the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC purchased a new position in Solventum in the fourth quarter valued at about $26,000. Crews Bank & Trust bought a new position in Solventum in the fourth quarter worth about $32,000. Synergy Asset Management LLC purchased a new stake in shares of Solventum during the fourth quarter valued at about $35,000. Finally, Spire Wealth Management bought a new stake in shares of Solventum in the 4th quarter valued at about $37,000.

Solventum Stock Performance

SOLV opened at $76.29 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The firm has a 50 day moving average of $75.60 and a two-hundred day moving average of $71.97. The firm has a market capitalization of $13.20 billion and a PE ratio of 27.74.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Wells Fargo & Company increased their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. The Goldman Sachs Group boosted their target price on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Piper Sandler raised their price target on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Finally, Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.